Progyny (PGNY) Tops Q4 EPS by 11c, Guidance Misses Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Progyny, Inc. Announces Fourth Quarter and Full Year 2021 Results
February 28, 2022 4:05 PM ESTIssues Guidance for 2022, Reflecting 50% Revenue Growth at Midpoint of the RangeReports Full Year Revenue of $500.6 Million, Reflecting 45% GrowthReports Fourth Quarter Revenue of $127.6 Million, Reflecting 27% Growth
NEW YORK, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced its financial results for the three- and twelve-month periods ended December 31, 2021 (the fourth quarter of 2021 and the full year, respectively) as compared to the three- and twelve-month periods ended December 31, 2020 (the fourth quarter of 2020 and the prior year period,... More
